Abstract
In this article are reviewed available experimental and clinical studies on vitamin D analogs, and molecular and cellular mechanisms of their antineoplastic activity. In more detail are discussed the antiproliferative and pro-differentiative effects, inhibition of tumor-induced angiogenesis and induction of apoptosis. The use of vitamin D analogs is however hampered by their toxicity. In various experimental systems it was shown that the activities of vitamin D analogs can be enhanced by combined application with retinoids or other biological active compounds, such as cytokines and growth factors. Retinoids and vitamin D analogs were found to have synergistic inhibitory effects on tumor cell proliferation and angiogenic capability, and both agents applied simultaneously are efficacious in small doses. Thus combined therapy could find application in clinical practice. There are up to now only very limited data on the treatment of cutaneous malignancies with vitamin D analogs, and it appears that a combined therapy, preferably with retinoids, could be more beneficial. The new synthetic, more potent and less calcemic analogs might find wide application in chemotherapy of premalignant and early malignant cutaneous tumors, and could be especially useful for chemoprevention in the high-risk groups, eg. xeroderma pigmentosum, organ transplant recipients, arsenical keratoses and others.
Keywords: Vitamin D Analogs, Cutaneous Malignancies, Cell Proliferation, receptor VDR, JCA 1 cell line, MCF6, DMBA, Cervical Tumors, Transglutaminase K, Cytokeratin 10, Ki 60, Immortalized keratinocyte HPKIA, Cancer, Immunosuppressive, Angiogenesis, Retinoids, Cytokines
Current Pharmaceutical Design
Title: Vitamin D Analogs in Cutaneous Malignancies
Volume: 6 Issue: 7
Author(s): Slawomir Majewski, Andrzej Kutner and Stefania Jablonska
Affiliation:
Keywords: Vitamin D Analogs, Cutaneous Malignancies, Cell Proliferation, receptor VDR, JCA 1 cell line, MCF6, DMBA, Cervical Tumors, Transglutaminase K, Cytokeratin 10, Ki 60, Immortalized keratinocyte HPKIA, Cancer, Immunosuppressive, Angiogenesis, Retinoids, Cytokines
Abstract: In this article are reviewed available experimental and clinical studies on vitamin D analogs, and molecular and cellular mechanisms of their antineoplastic activity. In more detail are discussed the antiproliferative and pro-differentiative effects, inhibition of tumor-induced angiogenesis and induction of apoptosis. The use of vitamin D analogs is however hampered by their toxicity. In various experimental systems it was shown that the activities of vitamin D analogs can be enhanced by combined application with retinoids or other biological active compounds, such as cytokines and growth factors. Retinoids and vitamin D analogs were found to have synergistic inhibitory effects on tumor cell proliferation and angiogenic capability, and both agents applied simultaneously are efficacious in small doses. Thus combined therapy could find application in clinical practice. There are up to now only very limited data on the treatment of cutaneous malignancies with vitamin D analogs, and it appears that a combined therapy, preferably with retinoids, could be more beneficial. The new synthetic, more potent and less calcemic analogs might find wide application in chemotherapy of premalignant and early malignant cutaneous tumors, and could be especially useful for chemoprevention in the high-risk groups, eg. xeroderma pigmentosum, organ transplant recipients, arsenical keratoses and others.
Export Options
About this article
Cite this article as:
Majewski Slawomir, Kutner Andrzej and Jablonska Stefania, Vitamin D Analogs in Cutaneous Malignancies, Current Pharmaceutical Design 2000; 6 (7) . https://dx.doi.org/10.2174/138161200780574593
DOI https://dx.doi.org/10.2174/138161200780574593 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Transcriptionally Targeted Adenovirus Vectors
Current Gene Therapy The Functional Role of Oncogenic LncRNA BCAR4 for Cancer Outcome
Current Pharmaceutical Design Commercial Availability of Alpha-Emitting Radionuclides for Medicine
Current Radiopharmaceuticals APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
Current Molecular Pharmacology Cancer and Treatment Modalities
Current Cancer Therapy Reviews MDM2 Increases Drug Resistance in Cancer Cells by Inducing EMT Independent of p53
Current Medicinal Chemistry Ceramide: Therapeutic Potential in Combination Therapy for Cancer Treatment
Current Drug Metabolism The Synergistic Use of Computation, Chemistry and Biology to Discover Novel Peptide-Based Drugs: The Time is Right
Current Pharmaceutical Design Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance
Mini-Reviews in Medicinal Chemistry Systematic Analysis of RNAi Reports Identifies Dismal Commonality at Gene-Level and Reveals an Unprecedented Enrichment in Pooled shRNA Screens
Combinatorial Chemistry & High Throughput Screening Drugs of Abuse: Epigenetic Mechanisms in Toxicity and Addiction
Current Medicinal Chemistry Lipid Rafts, Endoplasmic Reticulum and Mitochondria in the Antitumor Action of the Alkylphospholipid Analog Edelfosine
Anti-Cancer Agents in Medicinal Chemistry Cryopreservation of Ovarian Tissue: State of the Art in 2007
Current Women`s Health Reviews Functions and Mechanisms of Green Tea Catechins in Regulating Bone Remodeling
Current Drug Targets Glutathione Transferases as Targets for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Pathobiology and Prevention of Cancer Chemotherapy-Induced Bone Growth Arrest, Bone Loss, and Osteonecrosis
Current Molecular Medicine Mining Sarcomas by Proteomics Approaches: Ewing Sarcoma on the Spotlight
Recent Patents on Biotechnology Management of Osteoporosis: Seeing the Future
Medicinal Chemistry Reviews - Online (Discontinued) Cucurbitacin B Induces DNA Damage, G2/M Phase Arrest, and Apoptosis Mediated by Reactive Oxygen Species (ROS) in Leukemia K562 Cells
Anti-Cancer Agents in Medicinal Chemistry Mitocans: Mitochondrial Targeted Anti-Cancer Drugs as Improved Therapies and Related Patent Documents
Recent Patents on Anti-Cancer Drug Discovery